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tion of renal replacement therapy, cardiac performance tory hypertrophy is the major long-time evolutionary
pattern” and that “intervention beyond one year maymay change as a function of PTH level but not as the
be relatively ineffective.”effect of duration of therapy. Such a possibility is sug-
The fact that better results were obtained with perito-gested by the data presented in Table 3. Results given
neal dialysis may simply be due to better volume controlin the second and third columns show that cardiac mass,
in those patients. Other studies [2] have shown that thisvolume and function indexes deteriorate in some pa-
is not always the case. The absence of a relationship withtients but improve or do not change in others. The differ-
blood pressure could be related to the confounding effectences may depend on mode of dialysis and PTH concen-
of antihypertensive drugs, but probably also to an inde-tration.
pendent effect of volume retention.Therapy with EPO leads to the regression of LVH in
We recently showed [3] that prolonged strict volumedialysis patients. The mean hemoglobin level in the study
control can cause regression of dilatation and hypertro-group presented in the first column of Table 4 is 8.6 g/dl
phy of the left ventricle while abolishing the need for(range, 8.1–9.2), but the data plotted in Figure 1 reveal
antihypertensive drugs. An extreme example of a patientthat as many as 9 HD patients had a hemoglobin level
in whom volume control caused complete regression ofbelow 8 g/dl. We are curious as to whether these patients,
severe cardiomyopathy without hypertension [4] illus-particularly those with hemoglobin levels of 6–7 g/dl,
trates the importance of hypervolemia as an independentwere given EPO. If yes, it should be mentioned, because
risk factor. Clearly (as Foley et al stressed in earlierthis hormone affects cardiac function regardless of renal
publications) only intervention studies can definitely re-replacement therapy. If EPO was not given to these
solve the complicated problems of dialysis morbidity.patients, one wonders why the authors did not address
the severe anemia. Hu¨seyin To¨z, Mehmet O¨zkahya,
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To the Editor: We would like to thank all the corre-
spondents for their interest and helpful queries and com-
To the Editor: We would like to comment on the study ments.
of Foley et al [1]. In our opinion it is not correct to speak Dr. Erturk makes several reasonable points. It cer-
about the “natural history of cardiomyopathy” because tainly would have been of interest to look at the potential
the development of this cardiomyopathy is highly depen- role of post-dialysis blood pressures in the hemodialysis
dent on the way patients are treated, particularly the patients. The short answer is that we did not record
extent to which the treating team succeeds in controlling them, partly reflecting the fact that the study began in
“volume.” the early 1980s. It is hardly fair to say that post-dialysis
The fatalistic attitude that unfortunately prevails in blood pressure is a better predictor of LV mass index
many dialysis centres is supported by the conclusion that than pre-dialysis blood pressure. We have previously
shown, in a prospective cohort study of over a thousand“progressive left ventricular dilatation with compensa-
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patient years follow-up, that high pre-dialysis blood pres- tried to collect PTH levels. However, the data were unus-
able, largely reflecting the methodological heterogeneitysure strongly (and independently) pre-dates progressive
left ventricular enlargement [1]. Cohort studies have in measuring PTH in the 1980s.
Dr Toz and colleagues are quite right in pointing outclear advantages over cross-sectional designs, not the
least of which is the inability to tell the chicken from that this is not a natural history study in the strict sense
of the term, because intervention took place throughoutthe egg. It is hard to tell from an observational study
like this why, for example, an ACE inhibitor is used the study. We did not intend to engender fatalism in this
study. We wished to suggest that a pro-active approachin one patient, and a calcium blocker in another. As
exemplified in the recent calcium channel blocker de- may be superior with respect to known modifiable risk
factors. Clearly, we are very far from knowing all thebate, randomized controlled trials are a much better
vehicle to address this type of issue. The point is well modifiable risk factors for long-term LV enlargement.
We fully endorse the sentiment that intervention trials,taken, however. It is true that progressive LV enlarge-
ment slowed down beyond the first year. However, it many of them, are needed to resolve the complicated
problems of cardiovascular morbidity in dialysis patients.did not stop. We agree that blood pressure levels are
relatively good. Several studies, published long after this
Robert N. Foley
study began, show that hemoglobin levels of 8.6 g/dl Division of Nephrology, Memorial University of Newfoundland,
are sub-optimal, and likely to promote LV enlargement. The Health Sciences Center, St. John’s, Newfoundland, Canada
Four facts remain from our study. First, progressive LV
enlargement was strongly associated with anemia in the REFERENCES
first year. Second, progressive LV enlargement contin- 1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC,
ued to occur after year 1. Third, hemoglobin levels, if Barre PE: Impact of hypertension on cardiomyopathy, morbidity
and mortality in end-stage renal disease. Kidney Int 49:1379–1385,anything, were worse in years 2 and 3 than in year 1.
1996Fourth, the LV enlargement seen after one year was
not associated with the observed hemoglobin levels. The
contrast between a strong early association and an absent High serum IgE levelslater association is certainly striking; ours is one of many
possible interpretations. We agree wholeheartedly that are associated withcontrol of currently known risk factors needs to be opti-
mized at all times. However, what constitutes optimal selective proteinuriatreatment for an individual patient may change over
time. Therein lies a major challenge! in glomerulonephritisDr Strozecki and colleagues also make several reason-
able points. We fully admit that this is a small, highly- To the Editor: We were interested to read the paper
selected subgroup. However, it is self-selected, demon- by Ehara and Shigematsu on mast cells in IgA nephritis
strably, in response to the following pressures: staying [1] and wish to report our data supporting a potential
alive, and not receiving a transplant for a long period role of type I hypersensitivity in glomerulonephritis
of time. This was a study of differences in time in left (GN). The mechanisms ultimately resulting in protein-
ventricular characteristics. One of the advantages of a uria in GN are now better understood. An autoimmune
repeated measures design like this is that it minimizes basis with genetic susceptibility, leading to glomerular
the impact of known fixed characteristics (like age, diabe- injury by non-inflammatory and inflammatory mecha-
tes, sex and original kidney disease) and unknown fixed nisms and triggered by an antibody-antigen interaction,
characteristics. It is much more likely that a change in is likely. Type I hypersensitivity in GN, however, has
LV morphology or function would cause heart failure not been extensively studied, although the association of
than vice versa, so that enumerating who did and did atopy in minimal change disease and nephrotic syndrome
not develop heart failure is somewhat of a side issue due to allergens (food and insect stings) and infections
when looking at temporal trends in LV parameters. We (parasites and others) is well recognized. IgE typically
agree that peritoneal dialysis and hemodialysis patients binds to mast cells and basophils but also to low-affinity
need to be analyzed separately. One of the reasons for receptors on inflammatory cells and platelets, with the
using data from both peritoneal dialysis and hemodialy- release of inflammatory mediators and chemotactic fac-
sis patients was to compare the therapies with regard to tors that have been incriminated in GN. Evidence sup-
LV parameters. We have checked things separately and porting the role of type I hypersensitivity in the patho-
the associations are similar. This is not too surprising genesis of GN comes from reports of high levels of serum
with such small sample sizes. Figure 1 illustrates this
for hemoglobin levels. Alkaline phosphatase levels were
unassociated with progression in this set of patients. We  1999 by the International Society of Nephrology
